Phacilitate Leaders World 

Demystifying the Common Technical Document

Demystifying the Common Technical Document

The Common Technical Document can sometimes be a bit daunting. As a fundamental part of the approval process for your product, whether you are a huge multinational corporation or a small biotech company, it is essential to know how to use the CTD.

As more cell and gene therapies move towards commercialization, it is important to know how to adapt the CTD for your advanced therapy.

In the below guide, Chris Bravery, Consulting Regulatory Scientist of Advanced Biologicals, provides real-world examples of how to interpret and successfully complete the CTD, with particular focus on the following four techniques...

  1. Applying the CTD to advanced therapies
  2. Understanding section names
  3. Batch analysis
  4. Refining your writing style

 


 

 

 

 

 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK